Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
Kataoka K, Mori K, Nakamura Y, Watanabe J, Akazawa N, Hirata K, Yokota M, Kato K, Kotaka M, Yamazaki K, Kagawa Y, Mishima S, Ando K, Miyo M, Yukami H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kotani D, Bando H, Taniguchi H, Takemasa I, Kato T, Yoshino T, Oki E. Kataoka K, et al. Among authors: mishima s. Ann Oncol. 2024 Nov;35(11):1015-1025. doi: 10.1016/j.annonc.2024.08.2240. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293512 Free article.
A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, Yoshino T, Sasser K, Oki E, Nimeiri H. Nakamura Y, et al. Among authors: mishima s. Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396. Online ahead of print. Clin Cancer Res. 2024. PMID: 39513962
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer.
Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K. Jubashi A, et al. Among authors: mishima s. Gastric Cancer. 2025 Jan;28(1):63-73. doi: 10.1007/s10120-024-01560-z. Epub 2024 Nov 2. Gastric Cancer. 2025. PMID: 39487862 Free PMC article.
ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. Nakamura Y, et al. Among authors: mishima s. Nat Med. 2024 Nov;30(11):3272-3283. doi: 10.1038/s41591-024-03254-6. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284954 Free PMC article.
The longitudinality of care from the perspective of Family Health users.
Maciel AMM, Lettiere-Viana A, Mishima SM, Fermino TZ, Matumoto S. Maciel AMM, et al. Among authors: mishima sm. Rev Esc Enferm USP. 2024 Sep 13;58:e20240051. doi: 10.1590/1980-220X-REEUSP-2024-0051en. eCollection 2024. Rev Esc Enferm USP. 2024. PMID: 39283215 Free PMC article.
431 results